The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of pharmacokinetic (PK) modeling and simulations in selecting anti-SEMA4D antibody dose for phase I study in patients with advanced malignancies.
A. F. Nasser
No relevant relationships to disclose
B. Budda
Consultant or Advisory Role - Balasubrahmanyam Budda (U)
C. A. Cornelius
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
T. Fisher
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
L. A. Winter
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex
J. E. Leonard
Employment or Leadership Position - Vaccinex
Stock Ownership - Vaccinex